• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Mangoceuticals Inc.

    4/1/25 5:00:43 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MGRX alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on April 1, 2025

     

    Registration No. 333- ________

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    MANGOCEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     

    Texas   87-3841292
    (State or other jurisdiction
    of incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    15110 N. Dallas Parkway, Suite 600

    Dallas, Texas

      75248
    (Address of principal executive offices)   (Zip Code)

     

    SECOND AMENDED AND RESTATED

    MANGOCEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

    Jacob D. Cohen

    Chief Executive Officer

    Mangoceuticals, Inc.

    15110 N. Dallas Parkway, Suite 600

    Dallas, Texas 75248

    (Name and address of agent for service)

     

    (214) 242-9619

    (Telephone number, including area code, of agent for service)

     

    Copy to:

    David M. Loev, Esq.

    John S. Gillies, Esq.

    The Loev Law Firm, PC

    6300 West Loop South, Suite 280

    Bellaire, Texas 77401

    Telephone: (713) 524-4110

    Facsimile: (713) 524-4122

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    Registration of Additional Shares Pursuant to General Instruction E

     

    Pursuant to General Instruction E of Form S-8, Mangoceuticals, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 9,200,000 additional shares of Common Stock under the Registrant’s Second Amended and Restated 2022 Equity Incentive Plan (the “2022 Plan”), pursuant to an amendment to the 2022 Plan increasing the number of shares reserved for issuance thereunder by 9,200,000 shares, effective as of March 17, 2025. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on April 18, 2023 (Registration No. 333-271321) and May 14, 2024 (Registration No. 333-279391). In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

     

     

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed with the Commission by the Company are incorporated by reference into this registration statement on Form S-8 (the “Registration Statement”) and are made a part hereof:

     

      (a) The Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 20, 2025 (File No. 001-41615)(the “Annual Report”);
         
      (b) The Company’s Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on January 8, 2025, January 15, 2025, January 21, 2025, January 31, 2025, February 7, 2025, February 12, 2025, February 12, 2025, February 19, 2025, March 19, 2025, March 25, 2025 and March 28, 2025 (File No. 001-41615);
         
      (c) The description of the Company’s Common Stock contained in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on April 1, 2024, as Exhibit 4.5 (File No. 001-41615), including any amendment or report filed for the purpose of updating such description; and
         
      (d) All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since the end of the fiscal year covered by the Annual Report referred to in (a) above.

     

    All reports and documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 5. Interests of Named Experts and Counsel

     

    The validity of the common stock covered by this prospectus will be passed upon by The Loev Law Firm, PC. David M. Loev, the Managing Partner, President and sole owner of The Loev Law Firm, PC, beneficially owns less than 1% of the outstanding shares of our common stock and is the brother-in-law of Jacob D. Cohen, our Chairman and Chief Executive Officer.

     

     

     

     

    Item 8. Exhibits

     

            Incorporated by Reference
    Exhibit No.   Description   Form   File No.   Exhibit   Filing
    Date
      Filed Herewith
    4.1   Certificate of Formation of Mangoceuticals, Inc., filed with the Secretary of State of Texas on October 7, 2021   S-1   333-269240   3.1   1/13/2023    
    4.2   Certificate of Amendment to Certificate of Formation of Mangoceuticals, Inc., filed with the Secretary of State of Texas on April 15, 2022   S-1   333-269240   3.2   1/13/2023    
    4.3   Certificate of Amendment to Certificate of Formation, as amended and restated of Mangoceuticals, Inc., filed with the Secretary of State of Texas on October 8, 2024   8-K   001-41615   3.1   10/11/2025    
    4.4   Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., submitted to the Secretary of State of Texas on March 28, 2024   8-K   001-41615   3.3   4/1/2024    
    4.5   Certificate of Designations, Preferences and Rights of 6% Series C Convertible Preferred Stock of Mangoceuticals, Inc., filed with the Secretary of State of Texas on April 19, 2024   8-K   001-41615   3.1   4/25/2024    
    4.6   Certificate of Correction to Certificate of Designations, Preferences and Rights of 6% Series C Convertible Preferred Stock of Mangoceuticals, Inc., filed with the Secretary of State of Texas on April 29, 2024   8-K   001-41615   3.1   5/2/2024    
    4.7   Amendment to Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., filed with the Secretary of State of Texas on June 27, 2024   8-K   001-41615   3.2   7/2/2024    
    4.8   Amendment to Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., submitted to the Secretary of State of Texas on March 17, 2025   8-K   001-41615   3.3   3/19/2025    
    4.9   Bylaws of Mangoceuticals, Inc.   S-1   333-269240   3.3   1/13/2023    
    5.1*   Opinion of The Loev Law Firm, PC                   X
    23.1*   Consent of Turner, Stone & Company, L.L.P.                   X
    23.2*   Consent of The Loev Law Firm, PC (included in Exhibit 5.1)                   X
    24.1*   Power of Attorney (included on the signature page of this registration statement)                    
    99.1   Second Amended and Restated Mangoceuticals, Inc. 2022 Equity Incentive Plan   8-K   001-41615   10.2   3/19/2025    
    99.2   Form of Notice of Stock Option Grant and Stock Option Agreement (2022 Equity Incentive Plan) ***   S-8   333-271321    99.4   4/18/2023    
    99.3   Form of Notice of Restricted Stock Grant and Restricted Stock Grant Agreement (2022 Equity Incentive Plan) ***   S-8   333-271321    99.5   4/18/2023    
    99.4   Form of Notice of Restricted Stock Unit Grant and Restricted Stock Unit Agreement (2022 Equity Incentive Plan) ***   S-8   333-271321    99.6   4/18/2023    
    107*   Filing Fee Table                    

     

    * Filed herewith.
       
    *** Indicates management contract or compensatory plan or arrangement.

     

     

     

     

    Item 9. Undertakings

     

    (a) The Company hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the Form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    However, paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, our company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Dallas, State of Texas on the 1st day of April 2025.

     

      MANGOCEUTICALS, INC.
         
        /s/ Jacob D. Cohen                    
      By: Jacob D. Cohen, Chief Executive Officer and Chairman (Principal Executive Officer)

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mr. Jacob D. Cohen, with full power of substitution, re-substitution and authority to act, as his or her true and lawful attorneys-in-fact and agents, with full power for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Jacob D. Cohen   Chief Executive Officer and Chairman   April 1, 2025
    Jacob D. Cohen   (Principal Executive Officer)    
             
    /s/ Eugene M. Johnston   Chief Financial Officer   April 1, 2025
    Eugene M. Johnston   (Principal Financial and Accounting Officer)    
             
    /s/ Lorraine D’Alessio   Director   April 1, 2025
    Lorraine D’Alessio        
             
    /s/ Alex P. Hamilton   Director   April 1, 2025
    Alex P. Hamilton        
             
    /s/ Dr. Kenny Myers   Director   April 1, 2025
    Dr. Kenny Myers        
             
    /s/ Antonios Isaac   Director   April 1, 2025
    Antonios Isaac        

     

     

     

    Get the next $MGRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

      DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

      4/25/25 9:00:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care

    $MGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

      SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

      8/27/24 7:45:22 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

      SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

      6/5/24 5:15:19 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care

    $MGRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

      DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

      4/25/25 9:00:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada

      Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into a Master Distribution Agreement (the "Agreement") to secure the exclusive licensing and distribution rights for Diabetinol® within the United States and Canada. Diabetinol® is a plant-based nutraceutical clinically supporte

      3/25/25 9:00:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

      Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women's health and wellness brand focused on providing cutting-edge, convenient treatments tailored to women's unique health needs. These new and innovative women's health and wellness products will be made available via a secure telemedicine platform located at www.PeachesRx.com. PeachesRx will debut with a strong focus on compounded GLP-1 receptor agoni

      2/20/25 7:00:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care

    $MGRX
    SEC Filings

    See more
    • Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

      5/23/25 5:27:00 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Mangoceuticals Inc.

      10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)

      5/15/25 4:58:17 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

      5/6/25 5:01:36 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care

    $MGRX
    Financials

    Live finance-specific insights

    See more
    • Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

      Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi

      12/19/24 5:33:00 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

      Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial

      8/15/24 9:25:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care

    $MGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Isaac Antonios claimed no ownership of stock in the company (SEC Form 3)

      3 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

      1/21/25 4:30:13 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Johnston Eugene M was granted 25,000 shares, increasing direct ownership by 187% to 38,334 units (SEC Form 4)

      4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

      11/12/24 5:06:32 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Chief Executive Officer Cohen Jacob D. gifted 800,000 shares and received a gift of 800,000 shares (SEC Form 4)

      4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

      8/27/24 7:41:46 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care